Peptides Derived from a Distinct Region of GB Virus C Glycoprotein E2 Mediate Strain-Specific HIV-1 Entry Inhibition
Authors:
- 15 July 2011
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (14) , 7037-7047
Abstract
The nonpathogenic human GB virus C (GBV-C), a member of the Flaviviridae , is highly prevalent in individuals with HIV-1 infections or with parenteral and sexual risk factors. Long-term GBV-C viremia has been associated with better survival or improved diagnosis in several epidemiological studies. In a previous study we reported that the E2 glycoprotein of GBV-C interferes with HIV-1 entry in vitro . To address the question what region of the E2 protein is involved in suppression of HIV-1 replication, we performed an E2-derived peptide scanning and determined the HIV-inhibitory activity of each peptide in HIV replication assays. We demonstrate here that peptides representing the N-terminal part of the E2 protein from amino acids (aa) 29 to 72 are able to inhibit efficiently HIV-1 replication in vitro . In particular, the peptides P6-2 (representing the E2-region from aa 45 to 64) and P4762 (aa 37 to 64) showed the highest potency in HIV replication assays performed on TZM-bl cells with 50% inhibitory concentrations between 0.1 and 2 μM. However, primary HIV-1 isolates representing clades A to H showed a high variability in their sensitivity to E2 peptides. Pseudovirus inhibition assays revealed that the sensitivity is determined by the gp120/gp41 envelope proteins. Using HIV-1 BlaM-Vpr-based fusion assays, we demonstrate that the E2-derived peptides prevent HIV-1 binding or fusion, presumably via interaction with the HIV-1 particle. Together, these findings reveal a new mechanism of viral interference, suggesting that the envelope protein E2 of GBV-C target directly HIV-1 particles to avoid entry of these virions.Keywords
This publication has 40 references indexed in Scilit:
- Effect of Synthetic Peptides Belonging to E2 Envelope Protein of GB Virus C on Human Immunodeficiency Virus Type 1 InfectionJournal of Medicinal Chemistry, 2010
- Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 InfectionPLOS Pathogens, 2010
- Synthetic Peptides of Hepatitis G Virus (GBV-C/HGV) in the Selection of Putative Peptide Inhibitors of the HIV-1 Fusion PeptideThe Journal of Physical Chemistry B, 2009
- Characterization of a Peptide Domain within the GB Virus C NS5A Phosphoprotein that Inhibits HIV ReplicationPLOS ONE, 2008
- Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion PeptideCell, 2007
- HIV entry inhibition by the envelope 2 glycoprotein of GB virus CAIDS, 2007
- An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4 + Jurkat T cellsProceedings of the National Academy of Sciences, 2006
- Thermodynamics of Binding of a Low-Molecular-Weight CD4 Mimetic to HIV-1 gp120Biochemistry, 2006
- GB virus C during the natural course of HIV-1 infectionAIDS, 2004
- Increased Mucosal Transmission but Not Enhanced Pathogenicity of the CCR5-Tropic, Simian AIDS-Inducing Simian/Human Immunodeficiency Virus SHIV SF162P3 Maps to Envelope gp120Journal of Virology, 2003